These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28919583)

  • 1. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro.
    Hosseini Ghatar R; Soltantoyeh T; Bahadori M; Khoshnoodi J; Golsaz Shirazi F; Jeddi Tehrani M; Amiri MM; Shokri F
    Iran J Immunol; 2017 Sep; 14(3):200-214. PubMed ID: 28919583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice.
    Sadri-Ardalani F; Ahmadi M; Hemmati A; Emami S; Farid S; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
    Iran J Immunol; 2017 Jun; 14(2):99-110. PubMed ID: 28630381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.
    Sadri-Ardalani F; Shabani M; Amiri MM; Bahadori M; Emami S; Sarrafzadeh AR; Noutash-Haghighat F; Jeddi-Tehrani M; Shokri F
    Tumour Biol; 2016 Jan; 37(1):1217-27. PubMed ID: 26282003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines.
    Mansouri-Fard S; Ghaedi M; Shokri MR; Bahadori T; Khoshnoodi J; Golsaz-Shirazi F; Jeddi-Tehrani M; Amiri MM; Shokri F
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):439-447. PubMed ID: 32102522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
    Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
    MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
    Deng W; Liu J; Pan H; Li L; Zhou C; Wang X; Shu R; Dong B; Cao D; Li Q; Wang Z
    J Immunother; 2018 Jan; 41(1):1-8. PubMed ID: 29232309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies.
    Rockberg J; Schwenk JM; Uhlén M
    Mol Oncol; 2009 Jun; 3(3):238-47. PubMed ID: 19393584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody.
    Amiri MM; Bahadori T; Soltantoyeh T; Hosseini-Ghatar R; Golsaz-Shirazi F; Jeddi-Tehrani M; Shokri F
    Iran J Immunol; 2019 Mar; 16(1):26-42. PubMed ID: 30864553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.
    Pedersen MW; Jacobsen HJ; Koefoed K; Dahlman A; Kjær I; Poulsen TT; Meijer PJ; Nielsen LS; Horak ID; Lantto J; Kragh M
    Mol Cancer Ther; 2015 Mar; 14(3):669-80. PubMed ID: 25612619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains.
    Hosseini Ghatar R; Soltantoyeh T; Bahadori T; Golara M; Hassannia H; Khosravi Eghbal R; Khoshnoodi J; Judaki MA; Golsaz-Shirazi F; Jeddi-Tehrani M; Amiri MM; Shokri F
    Asian Pac J Cancer Prev; 2017 Nov; 18(11):3103-3110. PubMed ID: 29172286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.
    Amiri MM; Golsaz-Shirazi F; Soltantoyeh T; Hosseini-Ghatar R; Bahadori T; Khoshnoodi J; Navabi SS; Farid S; Karimi-Jafari MH; Jeddi-Tehrani M; Shokri F
    Invest New Drugs; 2018 Apr; 36(2):171-186. PubMed ID: 28983766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
    Shin JW; Kim S; Ha S; Choi B; Kim S; Im SA; Yoon TY; Chung J
    Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31635022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
    de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
    MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
    Carvajal-Hausdorf DE; Schalper KA; Bai Y; Black J; Santin AD; Rimm DL
    Gynecol Oncol; 2017 Apr; 145(1):154-158. PubMed ID: 28196634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
    Ghedini GC; Ciravolo V; Tortoreto M; Giuffrè S; Bianchi F; Campiglio M; Mortarino M; Figini M; Coliva A; Carcangiu ML; Zambetti M; Piazza T; Ferrini S; Ménard S; Tagliabue E; Pupa SM
    J Cell Physiol; 2010 Oct; 225(1):256-65. PubMed ID: 20506359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
    Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
    Hao Y; Yu X; Bai Y; McBride HJ; Huang X
    PLoS One; 2019; 14(5):e0216095. PubMed ID: 31042744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.